Ultime notizie per  (OTC:LNAWS) Azioni

Morgan Stanley analyst Betsy Graseck maintains PNC Financial Services Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNC#NYSE">PNC</a>) with a Underweight and lowers the price target from $188 to $179.

News

Price Target

Analyst Ratings

Morgan Stanley Maintains Underweight on PNC Financial Services Gr, Lowers Price Target to $179

Rhythm Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) on Monday released topline results from the pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, for the treatment of <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">acquired hypothalamic obesity</a>.
Acquired hypothalamic obesity is&nbsp;a rare, non-genetic form of obesity resulting from damage to the hypothalamus, the brain region controlling energy balance, often caused by tumors, surgery, or radiation, leading to rapid weight gain <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44663146/rhythm-pharmaceuticals-announces-pivotal-phase-3-transcend-trial-meets-primary-endpoint-with-19-8-" rel="noreferrer noopener">and metabolic complications</a>.
The global trial met its primary endpoint with a statistically significant and clinically meaningful reduction in body mass index (BMI) with setmelanotide in adult and pediatric patients versus placebo.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42627167/rhythm-pharmaceuticals-obesity-treatments-target-less-crowded-space-analyst-sees-long-term-potential" rel="noreferrer noopener">Rhythm Pharmaceuticals&#8217; Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential</a>
Highlights from the topline data include:
<ul>
<li>-19.8% placebo-adjusted difference in BMI reduction (N=120).</li>
<li>The primary endpoint of mean BMI reduction was -16.5% from baseline for all patients on setmelanotide therapy (n=81) compared with +3.3% BMI change for patients on placebo (n=39) at 52 weeks.</li>
<li>80% of patients on setmelanotide achieved a BMI reduction of 5% or greater at 52 weeks.</li>
<li>-19.2% placebo-adjusted BMI reduction was achieved in adult patients (n=49) and -20.2% in patients younger than 18 (n=71) at 52 weeks.</li>
</ul>
The company says the global Phase 3 TRANSCEND trial is believed to be the largest and longest placebo-controlled trial to evaluate therapy for patients with acquired hypothalamic obesity. The double-blinded, 52-week trial enrolled 120 patients.
Clinically meaningful improvements were observed across key secondary endpoints at week 52, including:
<ul>
<li>83% of patients on setmelanotide therapy achieved 5% or greater reduction in BMI (n=33 patients 18 or older) or BMI Z-score reduction of 0.2 or greater points (n=48 patients younger than 18).</li>
<li>-1.4 placebo-adjusted mean change in the weekly average of the daily maximal hunger score for patients 12 years old or older (n=81) (p=0.003).</li>
</ul>
No new safety signals with setmelanotide were observed, in line with setmelanotide&#8217;s well-established and well-understood safety profile. Consistent with prior clinical experience, setmelanotide was generally well tolerated in the TRANSCEND study.
The most common treatment-emergent adverse events (affecting &gt;20% of participants) were nausea, vomiting, diarrhea, injection site reaction, skin hyperpigmentation, and headache. No serious adverse events leading to study discontinuation were reported.
Price Action: RYTM stock is up 15.60% at $54.27 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44651786/lamb-weston-may-keep-cutting-prices-to-win-back-market-share-but-demand-recovery-remains-uncertain-says-analyst" target="_blank" rel="noreferrer noopener">Lamb Weston May Keep Cutting Prices To Win Back Market Share, But Demand Recovery Remains Uncertain</a></li>
</ul>
Photo by earthphotostock via Shutterstock

Biotech

Health Care

General

RYTM

Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder

Morgan Stanley analyst Betsy Graseck maintains Bank of New York Mellon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) with a Overweight and lowers the price target from $98 to $94.

Morgan Stanley Maintains Overweight on Bank of New York Mellon, Lowers Price Target to $94

Morgan Stanley analyst Betsy Graseck maintains Wells Fargo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) with a Overweight and raises the price target from $79 to $80.

Morgan Stanley Maintains Overweight on Wells Fargo, Raises Price Target to $80

A chaotic and volatile session kicked off the new week on Wall Street, with a start that offers <a href="https://www.benzinga.com/markets">little reason for optimism.</a>
The S&amp;P 500 opened with a gap below 4,900 points, then fiercely rebounded in the first hour of trading before the gains swiftly evaporated. Sentiment further deteriorated after Donald Trump adopted a more aggressive tone toward China.
On Truth Social, Trump stated that China had imposed retaliatory tariffs of 34%, on top of what he described as already record-setting tariffs, despite prior warnings that such measures would be met with significantly higher U.S. tariffs. He added that if China did not reverse the 34% hike by April 8, the United States would respond with additional tariffs of 50%, effective the following day.
He also indicated that all discussions with China regarding their requested meetings would be terminated, while negotiations with other countries that had expressed interest in talks would begin immediately.
The European Union signaled openness to implementing a zero-for-zero tariff agreement on industrial goods with the United States.
By 12:40 p.m. ET, the S&amp;P 500 was down 0.8%, the Nasdaq 100 fell 0.2%, and the Dow dropped 1.4%. Every sector remained in the red, with real estate and materials leading the losses.
In commodities, gold slipped 1.2%, heading for its third consecutive session of declines, while oil prices fell 2.3% to $60 a barrel, now down 16% from last week&#8217;s highs.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), which had been spared from last week&#8217;s global market rout, joined the bloodbath over the weekend, dropping 6.4% on Sunday and holding at $78,000 on Monday.
<h2 class="wp-block-heading">Monday&#8217;s Performance In Major US Indices, ETFs</h2>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg %</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>17,363.12</td>
<td>-0.2%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,026.51</td>
<td>-0.9%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,806.00</td>
<td>-1.2%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>37,781.52</td>
<td>-1.4%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:40 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) eased 0.7% to $502.84.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) fell 1.2% to $378.31.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;eased 0.2% to $421.93.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 0.9% to 179.64.</li>
<li>The&nbsp;Consumer Staples&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>) outperformed, up 0.1%; the&nbsp;Real Estate&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>) lagged, down 2.2%.</li>
</ul>
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Major Gainers</h3>
<ul>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) up 9.03% to $32.51</li>
<li>Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) up 5.61% to $71.34</li>
<li>Hewlett Packard Enterprise (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) up 5.16% to $13.45</li>
<li>Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) up 4.74% to $61.89</li>
<li>EQT Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) up 4.65% to $48.26</li>
<li>Arista Networks Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) up 4.65% to $67.36</li>
<li>Microchip Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) up 4.64% to $37.90</li>
</ul>
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Major Losers</h3>
<ul>
<li>Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) down 5.39% to $32.91</li>
<li>Eversource Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ES#NYSE">ES</a>) down 5.12% to $55.35</li>
<li>Genuine Parts Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NYSE">GPC</a>) down 5.07% to $110.88</li>
<li>Lamb Weston Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) down 5.03% to $56.03</li>
<li>AutoZone, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) down 4.96% to $3,472.18</li>
<li>NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) down 4.80% to $54.50</li>
<li>The Home Depot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) down 4.77% to $337.01</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44667862/oil-crashes-to-60-per-barrel-as-recession-fears-grow">Oil Crashes To $60 Per Barrel As Global Recession Fears Grow</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Equities

Government

Large Cap

Macro Economic Events

Regulations

Broad U.S. Equity ETFs

Economics

Tech

ETFs

$BTC

ANET

SPDR Dow Jones Industrial Average ETF Trust

DLTR

LRCX

MCHP

SMCI

XLRE

Select Sector SPDR-Consumer Discretionary

Wall Street Turmoil Deepens As Trump Threatens Massive China Tariffs, Bitcoin Wobbles At $78K: What's Driving Markets Monday?

Wedbush tech analyst Dan Ives on Monday shared his thoughts on where investors may find safe havens with the tech industry as the market volatility continues under the uncertainty of <a href="https://www.benzinga.com/25/04/44665493/us-recession-countdown-has-begun-as-trump-tariffs-push-odds-to-45-goldman-sachs-warns">Trump's tariff policies.&nbsp;</a>
What To Know: In a note to investors released Monday, Ives gave more insight into his recent comments on the potential effects of the new tariff policies and which tech stocks could outperform the rest of the sector in the volatile market conditions.&nbsp;
Cybersecurity names could outperform other stocks in the tech sector, according to Ives.&nbsp;
Read Next: <a href="https://www.benzinga.com/25/04/44667862/oil-crashes-to-60-per-barrel-as-recession-fears-grow">Oil Crashes To $60 Per Barrel As Global Recession Fears Grow&nbsp;</a>
He listed ZScaler, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>), Palo Alto Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>), CrowdStrikeHoldings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) as "defensive names where investors could rotate from semis to software to hunker down during this Category 5 storm."&nbsp;
Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Apple, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) remain Ives' top names to own and even with "this massive near-term uncertainty it does not change their installed base, technology leadership, and long-term growth opportunities ," the Wedbush analyst said.&nbsp;
Ives reiterated his calls for President Donald Trump to begin negotiations to reduce or eliminate tariffs which have led to the most difficult investing landscape in his "25 years covering tech stocks on the Street."
Earnings estimates will need to be reevaluated by the Street and Ives warned that most companies will likely not offer any forward guidance on their upcoming Q1 conference calls.&nbsp;
"Today will be a scary day for investors (and us) … it will create opportunities and way oversold tech stocks but we need to essentially toss out the next few quarters and start to work with some new normal financial model for 2026 for valuations as this tariff situation settles into place during negotiations," Ives said.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44537429/cathie-wood-doubles-down-on-2600-tesla-stock-price-prediction">Cathie Wood Doubles Down On $2,600 Tesla Stock Price Prediction</a></li>
</ul>
Image: Shutterstock

Analyst Color

Movers

AAPL

CRWD

NVDA

PANW

Nvidia, Apple Top 'Names To Own': Cybersecurity Stocks To Outperform, Tech Analyst Dan Ives Says

Morgan Stanley analyst Mike Cyprys maintains BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) with a Overweight and lowers the price target from $1275 to $1124.

Morgan Stanley Maintains Overweight on BlackRock, Lowers Price Target to $1124

The Board of PureTech Health plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTC#NASDAQ">PRTC</a>, LSE: PRTC))) ("PureTech" or the "Company") notes the recent press speculation and confirms that it is in discussions with Nordic Capital Epsilon SCA, SICAV-RAIF (acting through its general partner Nordic Capital Epsilon GP SARL) ("Nordic Capital") regarding a possible cash offer to acquire the entire share capital of the Company.
A further announcement will be made as and when appropriate. There can be no certainty that any firm offer will be made for the Company, nor as to the terms on which any firm offer might be made.
In accordance with Rule 2.6(a) of the Code, Nordic Capital is required, by no later than 5.00 p.m. (London time) on 5 May 2025, being 28 days after the date of this announcement, to either announce a firm intention to make an offer for the Company in accordance with Rule 2.7 of the Code or announce that it does not intend to make an offer, in which case the announcement will be treated as a statement to which Rule 2.8 of the Code applies. This deadline can be extended with the consent of the Takeover Panel in accordance with Rule 2.6(c) of the Code.
The person responsible for arranging release of this announcement on behalf of PureTech is Charles Sherwood, General Counsel.
This announcement is being made without the consent of Nordic Capital.

Contracts

Asset Sales

PRTC

PureTech Health Confirms Ongoing Discussions With Nordic Capital Regarding Possible Cash Offer For Entire Share Capital, With A Decision Expected By May 5, 2025

Morgan Stanley analyst Michael Cyprys maintains Franklin Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEN#NYSE">BEN</a>) with a Underweight and lowers the price target from $18 to $15.

Morgan Stanley Maintains Underweight on Franklin Resources, Lowers Price Target to $15

Morgan Stanley analyst Rayna Kumar upgrades SEI Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEIC#NASDAQ">SEIC</a>) from Underweight to Overweight and lowers the price target from $81 to $77.

Upgrades

SEIC

Morgan Stanley Upgrades SEI Inv to Overweight, Lowers Price Target to $77

Trading Ideas

JNVR

Janover Shares Resume Trade

Morgan Stanley analyst Ryan Kenny maintains Moelis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MC#NYSE">MC</a>) with a Underweight and lowers the price target from $70 to $42.

Morgan Stanley Maintains Underweight on Moelis, Lowers Price Target to $42

A false report claiming the Trump administration was preparing a <a href="https://www.benzinga.com/25/04/44663112/us-families-to-see-3800-annual-price-hike-says-experts-even-as-trump-indicates-tariff-windfall-of-tens-of-billions-of-dollars">90-day pause on tariffs</a> triggered a wave of volatility across U.S. equity and crypto markets on Monday.
What Happened: The confusion began when an unverified post on X suggesting a temporary tariff halt made its way to CNBC's headline feed without confirmation.
The headline was later picked up by Reuters, further amplifying the misleading report. 
The White House quickly denied the claim, telling CNBC that no such policy was under consideration and labeling the headlines as "fake news."
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44664914/bitcoin-ethereum-xrp-dogecoin-obliterate-142-billion-in-liquidations-plummet-up-to-16">Bitcoin, Ethereum, XRP, Dogecoin Obliterate $1.42 Billion In Liquidations, Plummet Up To 16%</a>
Why It Matters: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) saw a sharp swing, rising above $520 at the open before tumbling below $495 shortly after the rumor was debunked.
The index's swing represented an approximate $2 trillion loss in market value, highlighting the fragility of investor sentiment amid ongoing trade policy tensions.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), too, responded sharply to the fake headline. 
The cryptocurrency surged from $77,500 to $80,800 within minutes as hopes of a tariff pause spread. 
But once the rumor was invalidated, BTC corrected back to around $78,000, giving up most of its gains.
Nasdaq futures were also caught in the turmoil, swinging in double-digit percentage ranges. 
Analysts attributed the erratic price action to a mix of headline-driven algorithmic trading and heightened market sensitivity to geopolitical and economic policy headlines.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44657151/ripple-warns-this-country-is-falling-behind-in-the-crypto-race">Ripple Warns: This Country Is Falling Behind In The Crypto Race</a></li>
</ul>
Image created using artificial intelligence with Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Bitcoin Whipsaws As Trillions In Market Value Are Erased On Fake Tariff Pause Rumor

CLIK

Click Shares Resume Trade Following Circuit Breaker Halt

"Market reverses on volatility after White House reportedly alleges '90-day tariff pause' headline circulated by notable X accounts is 'fake news'"
 &nbsp;

WIIM

SUNE

SUNation Energy shares are trading lower. The company announced it closed the final tranche of its registered direct offering.

Morgan Stanley analyst Ryan Kenny maintains Houlihan Lokey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLI#NYSE">HLI</a>) with a Overweight and lowers the price target from $190 to $156.

Morgan Stanley Maintains Overweight on Houlihan Lokey, Lowers Price Target to $156

EQNR

SHEL

Shares of energy stocks are trading lower as crude oil falls to 2021 levels, following OPEC+'s decision to accelerate production hikes. The market is also grappling with fears of a recession, fueled by President Trump's recent tariff announcements and China's retaliatory measures, which have heightened concerns over global demand.

Morgan Stanley analyst Ryan Kenny downgrades Lazard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) from Equal-Weight to Underweight and lowers the price target from $56 to $33.

Downgrades

Morgan Stanley Downgrades Lazard to Underweight, Lowers Price Target to $33

Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) is giving investors some good news — especially if they're keeping a close eye on its <a href="https://www.benzinga.com/quote/VRTX/news">newly launched painkiller Journavx</a>.
<h1 class="wp-block-heading">Journavx Gains Early Traction</h1>
At the 2025 Napa Valley Biotech Forum, JPMorgan analyst Jessica Fye walked away with a bullish tone after conversations with Vertex CEO Reshma Kewalramani and Senior Vice President of Investor Relations Susie Lisa.
The message is that Journavx is off to a strong start in its acute pain debut, with good momentum across hospital and retail settings and broad shelf availability, reportedly on close to 90% of U.S. pharmacy shelves.
Coverage is picking up faster than anticipated, and while the drug is mostly placed in Tier 3 for now, management downplayed the concern. "It's all about overall value," they emphasized, as anecdotal reports suggest that both prescribing physicians and patients are seeing encouraging results.
Read Also: <a href="https://www.benzinga.com/insights/short-sellers/25/04/44591879/is-vertex-pharmaceuticals-gaining-or-losing-market-support">Is Vertex Pharmaceuticals Gaining or Losing Market Support?</a>
<h1 class="wp-block-heading">Two Levers To Watch In 2025</h1>
Fye highlighted that Vertex&#8217;s 2025 revenue guide of $11.75 billion to $12 billion is primarily powered by cystic fibrosis therapies, but she also noted "two potential upside levers" to that figure: 
<ul>
<li>A quicker-than-expected ramp-up for Journavx</li>
<li>Faster patient dosing for gene-editing therapy Casgevy.</li>
</ul>
The former is shaping up nicely already, while the latter, she noted, remains "a long journey."
<h1 class="wp-block-heading">Alyftrek and International Challenges</h1>
The company remains confident in Alyftrek, its next-gen cystic fibrosis drug with once-daily dosing and an expanded mutation profile.
There is, however, one international wrinkle: the expected revenue drag from Russia's disregard of Vertex's intellectual property rights. 
Still, with a high-quality profile and positive momentum in pain and gene therapy, Fye believes Vertex could continue to benefit from rotation in this macro backdrop.
JPMorgan reiterated its Overweight rating.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44652995/vertex-alnylam-best-positioned-as-biopharma-braces-for-tariff-impact-goldman-sachs-analyst-flags-regeneron-biogen-risks">Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks</a></li>
</ul>
Photo: Shutterstock

Comments

Notizie

Ultime notizie per (OTC:LNAWS) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO